公开(公告)号：WO2013000870A1

公开(公告)日：2013-01-03

申请号：PCT/EP2012/062258

申请日：2012-06-25

Applicant: GALDERMA RESEARCH & DEVELOPMENT ,  CARLAVAN, Isabelle

Inventor： CARLAVAN, Isabelle

IPC: C12Q1/68

CPC classification number: C12Q1/6883 ,  C12Q2600/158 ,  G01N33/505 ,  G01N33/6863 ,  G01N33/6869 ,  G01N2800/52

Abstract: The invention is directed to the use of IL-12R 1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 crucial actors in Thl7 cells differentiation as new markers for acne, and their use to diagnose acne, to screen inhibitors of Th17 differentiation, notably in inhibiting IL-12R 1/IL-23R, CCR6, BATF, AHR, STAT3,IRF4 and the use of these screened inhibitors in acne treatment.

Abstract translation: 本发明涉及IL-12R 1 / IL-23R，CCR6，BATF，AHR，STAT3，IRF4关键参与者在Th17细胞分化中作为痤疮的新标记物，以及它们用于诊断痤疮的用途，以筛选Th17的抑制剂 特别是抑制IL-12R 1 / IL-23R，CCR6，BATF，AHR，STAT3，IRF4以及这些筛选的抑制剂在痤疮治疗中的用途。

公开(公告)号：WO2012168484A1

公开(公告)日：2012-12-13

申请号：PCT/EP2012/061036

申请日：2012-06-11

Applicant: UNIVERSITÉ LIBRE DE BRUXELLES ,  BONE THERAPEUTICS SA ,  UNIVERSITÉ DE LIÈGE ,  CENTRE HOSPITALIER UNIVERSITAIRE DE LIÈGE ,  GANGJI, Valérie ,  HAUZEUR, Jean-Philippe ,  DE SENY, Dominique ,  MATHIEU, Myrielle ,  INGELS, Aude ,  RIGUTTO, Sabrina ,  SPRUYT, Delphine ,  BASTIANELLI, Enrico ,  ALBARANI, Valentina ,  PESESSE, Xavier ,  MAILAISE, Michel

Inventor： GANGJI, Valérie ,  HAUZEUR, Jean-Philippe ,  DE SENY, Dominique ,  MATHIEU, Myrielle ,  INGELS, Aude ,  RIGUTTO, Sabrina ,  SPRUYT, Delphine ,  BASTIANELLI, Enrico ,  ALBARANI, Valentina ,  PESESSE, Xavier ,  MAILAISE, Michel

IPC: G01N33/68 ,  A61K38/19

CPC classification number: C07K14/5421 ,  A61K38/2053 ,  G01N33/6863 ,  G01N33/6869 ,  G01N2333/522 ,  G01N2333/5412 ,  G01N2333/5421

Abstract: The application teaches a composition comprising one or more pharmaceutical active ingredients selected from the group consisting of interleukin-8 (IL-8 or CXCL8), a functional fragment of IL-8, a functional variant of IL-8, andan agonist of IL-8 receptor,for therapeutic and/orprophylactic interventions in impaired bone fracture healing, such as but not limited to non-union fractures, mal-union fractures,or delayed union fractures.

Abstract translation: 本申请教导了包含一种或多种选自白细胞介素-8（IL-8或CXCL8），IL-8的功能片段，IL-8的功能性变体和IL-8的激动剂的药物活性成分的组合物， 8受体，用于骨折愈合受损的治疗和/或预防性干预，例如但不限于非联合骨折，非联合骨折或延迟联合骨折。

公开(公告)号：WO2012135905A1

公开(公告)日：2012-10-11

申请号：PCT/AU2012/000348

申请日：2012-04-04

Applicant: HOWARD FLOREY INSTITUTE ,  KILPATRICK, Trevor ,  BINDER, Michele Denise ,  MA, Zhi-Ming Gerry

Inventor： KILPATRICK, Trevor ,  BINDER, Michele Denise ,  MA, Zhi-Ming Gerry

IPC: G01N33/68 ,  A61K38/17

CPC classification number: G01N33/566 ,  A61K38/215 ,  G01N33/6863 ,  G01N33/86 ,  G01N2333/745 ,  G01N2800/28 ,  G01N2800/285 ,  G01N2800/2871 ,  G01N2800/50 ,  G01N2800/52

Abstract: The present disclosure relates to the use of TAM receptor ligands, metabolites, precursor and binding partners thereof in the field of inflammatory neuropathology. This includes the early diagnosis and monitoring of an inflammatory neuropathology as well as screening for medicaments used in the treatment and prophylaxis of such a condition. The method comprises screening blood fluid from a subject for a TAM receptor ligand, or metabolite, or precursor thereof wherein an altered level of the ligand or its metabolite or precursor relative to a control is indicative of the presence of an inflammatory neuropathological disease or condition or a likelihood of developing the same. Diagnostic kits, high throughput screening assays and therapeutic compositions for inflammatory neuropathies are also taught herein.

Abstract translation: 本公开涉及在炎症性神经病理学领域中使用TAM受体配体，其代谢物，前体和结合配偶体。 这包括早期诊断和监测炎症性神经病理学以及筛选用于治疗和预防这种病症的药物。 该方法包括筛选TAM受体配体或代谢物或其前体的来自受试者的血液，其中配体或其代谢物或前体相对于对照的改变水平指示存在炎症性神经病理学疾病或病症或 发展同样的可能性。 本文还介绍了诊断试剂盒，高通量筛选测定法和炎性神经病变治疗组合物。

公开(公告)号：WO2012135332A1

公开(公告)日：2012-10-04

申请号：PCT/US2012/030923

申请日：2012-03-28

Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE ,  TUFTS MEDICAL CENTER, INC. ,  HU, Guofu ,  YU, Wenhao

Inventor： HU, Guofu ,  YU, Wenhao

IPC: C07K16/30 ,  C12P21/08 ,  A61K39/395

CPC classification number: C07K16/40 ,  A61K2039/505 ,  C07K14/71 ,  C07K14/715 ,  C07K16/28 ,  C07K16/30 ,  C07K2317/34 ,  C07K2317/73 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  G01N33/6863

Abstract: Disclosed herein are novel compositions and methods for the inhibition of Plexin B2- mediated Angiogenin activity. Such compositions and methods are useful, for example, for the treatment of cancer, the treatment of wet AMD and the inhibition of angiogenesis. Also disclosed herein are methods of determining whether a test agent is a modulator of Plexin B2 activity.

Abstract translation: 本文公开了用于抑制Plexin B2介导的血管生成素活性的新型组合物和方法。 这样的组合物和方法可用于例如治疗癌症，治疗湿性AMD和抑制血管发生。 本文还公开了确定测试剂是否是Plexin B2活性的调节剂的方法。

公开(公告)号：WO2012094300A3

公开(公告)日：2012-09-27

申请号：PCT/US2012020050

申请日：2012-01-03

Applicant: US HEALTH ,  NUSSENBLATT ROBERT ,  LIU BAOYING ,  WEI LAI

Inventor： NUSSENBLATT ROBERT ,  LIU BAOYING ,  WEI LAI

IPC: A61K39/395 ,  A61P27/00 ,  A61P27/02

CPC classification number: A61K39/3955 ,  A61K2039/505 ,  C07K16/244 ,  G01N33/573 ,  G01N33/6863 ,  G01N33/6893

Abstract: The present invention is directed to methods of treating and diagnosing age-related macular degeneration.

Abstract translation: 本发明涉及治疗和诊断年龄相关性黄斑变性的方法。

公开(公告)号：WO2012122236A2

公开(公告)日：2012-09-13

申请号：PCT/US2012/028011

申请日：2012-03-07

Applicant: BANNER RESEARCH INSTITUTE ,  COLEMAN, Paul D.

Inventor： COLEMAN, Paul D.

IPC: G01N33/53 ,  C12Q1/68 ,  G01N33/532 ,  G01N33/543

CPC classification number: C12Q1/6883 ,  C12Q2600/112 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/158 ,  G01N33/5308 ,  G01N33/6863 ,  G01N33/6896 ,  G01N2800/2821 ,  G01N2800/54 ,  G06F19/18 ,  G06F19/24

Abstract: Various embodiments provide methods for the detection, the diagnosis, and/or the prediction of disease onset of Alzheimer's disease. Methods for determining a state of Alzheimer's disease are provided. Accordingly, these methods can comprise the steps of placing a sample comprising at least one blood component onto a substrate, labeling the sample to identify at least one epigenetic marker and at least one of an inflammation marker and a cellular stress marker; determining an amount of the markers; performing a multivariate statistical analysis to produce an output value; comparing the output value to a reference value; and determining a state of Alzheimer's disease.

Abstract translation: 各种实施方案提供用于检测，诊断和/或预测阿尔茨海默病的疾病发作的方法。 提供了确定阿尔茨海默病状态的方法。 因此，这些方法可以包括以下步骤：将包含至少一种血液成分的样品放置在基底上，标记样品以鉴定至少一种表观遗传标记以及炎症标记和细胞应激标记中的至少一种; 确定标记的量; 执行多变量统计分析以产生输出值; 将输出值与参考值进行比较; 并确定阿尔茨海默病的状态。

公开(公告)号：WO2012037199A3

公开(公告)日：2012-08-23

申请号：PCT/US2011051523

申请日：2011-09-14

Applicant: UNIV JOHNS HOPKINS ,  LI XUHANG ,  ALEX PHILIP J ,  OKLAHOMA MED RES FOUND ,  CENTOLA MICHAEL B ,  KNOWLTON NICHOLAS

Inventor： LI XUHANG ,  ALEX PHILIP J ,  CENTOLA MICHAEL B ,  KNOWLTON NICHOLAS

IPC: G01N33/68 ,  C07K14/52 ,  G01N33/53

CPC classification number: G01N33/6863 ,  C07K14/52 ,  G01N33/6866 ,  G01N33/6869 ,  G01N2333/521 ,  G01N2333/522 ,  G01N2333/535 ,  G01N2333/5403 ,  G01N2333/5406 ,  G01N2333/5409 ,  G01N2333/5412 ,  G01N2333/5421 ,  G01N2333/5428 ,  G01N2333/5434 ,  G01N2333/545 ,  G01N2333/55 ,  G01N2333/57 ,  G01N2800/065 ,  G01N2800/60

Abstract: The present invention relates to the field of inflammatory bowel disease. More specifically, the present invention relates to the use of cytokines to detect, diagnose, and assess inflammatory bowel disease. In one embodiment, a method for diagnosing Crohn's Disease (CD) in a patient comprises the steps of (a) collecting a sample from the patient; (b) measuring the levels of at least one cytokine in the sample collected from the patient; and (c) comparing the levels of the at least one cytokine with predefined cytokine levels, wherein a correlation between the cytokine levels in the patient sample and predefined cytokine levels indicates that the patient has CD. In a specific embodiment, the at least one cytokine comprises Interferon (IFN)-gamma, Interleukin (IL)-1beta, IL-6, IL-8, IL-12, IL-17 and CXCL10.

Abstract translation: 本发明涉及炎症性肠病领域。 更具体地，本发明涉及细胞因子用于检测，诊断和评估炎症性肠病的用途。 在一个实施方案中，用于诊断患者中的克罗恩病（CD）的方法包括以下步骤：（a）从患者收集样品; （b）测量从患者收集的样品中至少一种细胞因子的水平; 和（c）将至少一种细胞因子的水平与预定的细胞因子水平进行比较，其中患者样品中的细胞因子水平与预定的细胞因子水平之间的相关性表明患者具有CD。 在一个具体的实施方案中，所述至少一种细胞因子包括干扰素（IFN）-γ，白介素（IL）-1β，IL-6，IL-8，IL-12，IL-17和CXCL10。

公开(公告)号：WO2012094300A2

公开(公告)日：2012-07-12

申请号：PCT/US2012/020050

申请日：2012-01-03

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services Office of Technology Transfer National Institutes of Health ,  NUSSENBLATT, Robert ,  LIU, Baoying ,  WEI, Lai

Inventor： NUSSENBLATT, Robert ,  LIU, Baoying ,  WEI, Lai

IPC: A61K39/395 ,  A61P27/02 ,  A61P27/00

CPC classification number: A61K39/3955 ,  A61K2039/505 ,  C07K16/244 ,  G01N33/573 ,  G01N33/6863 ,  G01N33/6893

Abstract: The present invention is directed to methods of treating and diagnosing age-related macular degeneration.

Abstract translation: 本发明涉及治疗和诊断年龄相关性黄斑变性的方法。

公开(公告)号：WO2012087928A2

公开(公告)日：2012-06-28

申请号：PCT/US2011/065830

申请日：2011-12-19

Applicant: THE ROCKEFELLER UNIVERSITY ,  RAVETCH, Jeffrey, V. ,  LI, Fubin

Inventor： RAVETCH, Jeffrey, V. ,  LI, Fubin

IPC: G01N33/53

CPC classification number: C07K16/2878 ,  A61K38/177 ,  A61K39/3955 ,  A61K2039/505 ,  C07K16/2851 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/71 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/75 ,  C07K2317/92 ,  C07K2319/00 ,  C07K2319/30 ,  G01N33/6863 ,  G01N2333/70535 ,  G01N2333/70578 ,  A61K31/00

Abstract: The instant invention relates to agents (e.g., agonistic antibodies) able to stimulate the immune system of a mammalian animal and activate target-cell specific T lymphocyte responses. Such agents may be identified based on the ability to engage a receptor from the TNFR Superfamily and thereby mimic the natural ligand for the receptor from the TNFR Superfamily. Modified antibodies of this class display enhanced immunostimulatory activity and may be formulated and administered for the treatment of a disease or disorder.

Abstract translation: 本发明涉及能够刺激哺乳动物的免疫系统并激活靶细胞特异性T淋巴细胞反应的药剂（例如激动性抗体）。 这些试剂可以基于从TNFR超家族中接受受体的能力来鉴定，并由此模拟来自TNFR超家族的受体的天然配体。 这类改性抗体显示出增强的免疫刺激活性，并且可以配制和施用用于治疗疾病或病症。

公开(公告)号：WO2012085652A2

公开(公告)日：2012-06-28

申请号：PCT/IB2011/003145

申请日：2011-12-22

Applicant: CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS ,  PANTALEO, Giuseppe ,  HARARI, Alexandre ,  PERREAU, Matthieu

Inventor： PANTALEO, Giuseppe ,  HARARI, Alexandre ,  PERREAU, Matthieu

IPC: G01N33/569

CPC classification number: G01N33/5695 ,  G01N33/6863 ,  G01N2333/35 ,  G01N2333/525 ,  G01N2333/55 ,  G01N2333/57

Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease.

Abstract translation: 本公开涉及用于区分具有活性和潜伏性结核病的哺乳动物的方法。